Zacks Research Issues Positive Estimate for Revvity Earnings

Revvity, Inc. (NYSE:RVTY) – Investment analysts at Zacks Research raised their FY2024 EPS estimates for Revvity in a report issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.84 for the year, up from their prior estimate of $4.74. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s Q4 2024 earnings at $1.36 EPS, Q3 2025 earnings at $1.28 EPS, Q4 2025 earnings at $1.46 EPS, Q1 2026 earnings at $1.33 EPS and Q3 2026 earnings at $1.42 EPS.

Several other equities analysts have also issued reports on the company. Wells Fargo & Company initiated coverage on Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 target price on the stock. Barclays decreased their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating for the company in a research report on Monday. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Robert W. Baird increased their price target on Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Raymond James boosted their price target on Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.73.

Revvity Trading Up 1.0 %

RVTY opened at $116.23 on Wednesday. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40. The firm has a market cap of $14.15 billion, a price-to-earnings ratio of 56.15, a PEG ratio of 2.86 and a beta of 1.05. Revvity has a 12 month low of $86.30 and a 12 month high of $129.50. The stock has a fifty day moving average price of $120.05 and a 200-day moving average price of $115.89.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The business had revenue of $684.10 million for the quarter, compared to the consensus estimate of $679.66 million. Revvity had a return on equity of 7.42% and a net margin of 9.34%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS.

Institutional Investors Weigh In On Revvity

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC boosted its holdings in shares of Revvity by 516.4% during the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after purchasing an additional 379,802 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Revvity by 3,171.3% in the second quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company’s stock valued at $9,142,000 after purchasing an additional 84,515 shares during the period. DekaBank Deutsche Girozentrale increased its position in Revvity by 27.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company’s stock worth $8,790,000 after purchasing an additional 18,367 shares during the last quarter. Virtu Financial LLC purchased a new position in Revvity during the first quarter worth about $1,214,000. Finally, Artemis Investment Management LLP raised its position in shares of Revvity by 21.3% during the 2nd quarter. Artemis Investment Management LLP now owns 107,634 shares of the company’s stock valued at $11,287,000 after buying an additional 18,916 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Revvity

In related news, insider Tajinder S. Vohra sold 2,153 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now owns 23,960 shares in the company, valued at $2,925,276.40. This represents a 8.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is owned by company insiders.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be given a $0.07 dividend. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s dividend payout ratio (DPR) is currently 13.53%.

Revvity declared that its Board of Directors has approved a stock buyback plan on Monday, November 4th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 6.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its stock is undervalued.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.